I 
119TH CONGRESS 
1ST SESSION H. R. 4395 
To provide for research and education with respect to uterine fibroids, and 
for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JULY 15, 2025 
Ms. CLARKE of New York (for herself, Ms. BROWN, Ms. KELLY of Illinois, 
Mrs. WATSON COLEMAN, Mr. DAVID SCOTT of Georgia, Ms. SEWELL, 
Mrs. FOUSHEE, Ms. NORTON, Ms. MCCLELLAN, Ms. VELA´ZQUEZ, Mr. 
FIELDS, Mrs. DINGELL, Ms. TLAIB, Mrs. TRAHAN, Mr. JOHNSON of 
Georgia, Mr. PETERS, Mr. FROST, Ms. ANSARI, Mr. THANEDAR, Ms. 
CASTOR
of 
Florida, 
Mr. 
THOMPSON
of 
Mississippi, 
Mr. 
KRISHNAMOORTHI, Ms. SALINAS, Mrs. MCIVER, Mr. CARTER of Lou-
isiana, Ms. MENG, Ms. WILSON of Florida, Ms. LEE of Pennsylvania, Ms. 
SIMON, Ms. WASSERMAN SCHULTZ, Mr. TAKANO, Ms. CRAIG, Mr. FIG-
URES, Ms. ADAMS, Mr. KHANNA, Mr. MEEKS, Ms. UNDERWOOD, Mr. 
GREEN of Texas, Ms. TOKUDA, Ms. RIVAS, and Mr. MANNION) intro-
duced the following bill; which was referred to the Committee on Energy 
and Commerce 
A BILL 
To provide for research and education with respect to uterine 
fibroids, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Stephanie Tubbs Jones 
Uterine Fibroid Research and Education Act of 2025’’. 
VerDate Sep 11 2014 
02:23 Jul 18, 2025
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H4395.IH
H4395
kjohnson on DSK7ZCZBW3PROD with $$_JOB
SEC. 2. FINDINGS. 
Congress finds as follows: 
(1) It is estimated that 20 percent to 50 per-
cent of women of reproductive age currently have 
uterine fibroids, and up to 77 percent of women will 
develop fibroids before menopause. 
(2) In the United States, an estimated 
26,000,000 women between the ages of 15 and 50 
have uterine fibroids, and approximately 15,000,000 
of these individuals experience symptoms. Uterine 
fibroids may cause significant morbidity through 
their presence in the uterus and pelvic cavity, and 
symptoms can include pelvic pain, severe menstrual 
bleeding, iron-deficiency anemia, fatigue, bladder or 
bowel dysfunction, infertility, and pregnancy com-
plications and loss. 
(3) The pain, discomfort, stress, and other 
physical and emotional symptoms of living with 
fibroids may significantly interfere with a woman’s 
quality of life, compromising her ability to function 
normally or work or care for her family, and may 
lead to more severe health and wellness issues. 
(4) Most women will experience uterine fibroids 
by the age of 50, yet few data exist describing the 
overall patient experience with fibroids. 
VerDate Sep 11 2014 
02:23 Jul 18, 2025
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H4395.IH
H4395
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(5) Many people with fibroids are likely 
undiagnosed. Patients wait on average 3.6 years be-
fore seeking treatment, and over 40 percent of pa-
tients see two or more health care providers prior to 
receiving a diagnosis, underscoring the need for im-
proved awareness and education. 
(6) People of color are more likely to develop 
uterine fibroids. It is estimated that more than 80 
percent of Black women and about 70 percent of 
White women develop fibroids by the time they reach 
menopause. Black individuals with fibroids have also 
been shown to have more severe symptoms and de-
velop early-onset uterine fibroids that develop into 
larger tumors. 
(7) Current research and available data do not 
provide adequate information on the prevalence and 
incidence of fibroids in Asian, Hispanic, and Black 
individuals. 
(8) Symptomatic uterine fibroids can cause re-
productive problems, including infertility. People 
with uterine fibroids are much more likely to mis-
carry during early pregnancy than people without 
them. 
(9) According to the Evidence Report Summary 
on the Management of Uterine Fibroids, as compiled 
VerDate Sep 11 2014 
02:23 Jul 18, 2025
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H4395.IH
H4395
kjohnson on DSK7ZCZBW3PROD with $$_JOB